UK RECOVERY researchers based out of the University of Oxford have discovered a potentially life-saving drug for people hospitalized with Covid-19. The drug, Regeneron’s REGEN-COV has been found to reduce 28 day mortality by 20%.
The drug essentially provides a boost for those patients who have been unable to create their own antibodies to the virus, and have tested negative to antibodies, known as seronegative patients. There may now be 6 fewer deaths of seronegative patients for every 100 that are treated with this drug.
This trial is notably the first to demonstrate the effectiveness of antibody-focused treatments in preventing deaths in hospitalized Covid-19 patients. The study involved 9,785 participants, one third of which showed no ability to produce their own antibodies. Mortality in this group was 30% when receiving standard care, but only 24% when receiving the REGEN-COV, as delivered via. Intravenous drip.
The REGEN-COV drug is a combination of two monoclonal antibodies which are designed to block the infectivity of Covid-19. The antibodies work by binding to two different points on the virus’s spike protein and neutralizing its infectious abilities.
Regeneron head of global clinical development, David Weinreich stated in an interview with Clinical Trials arena,“ The RECOVERY trial has shown that in patients who had not made their own antibodies against SARS-CoV-2, treating them with REGEN-COV antibodies dramatically reduced their risk of dying or being on a ventilator, and also shortened how many days they remained in the hospital.”
Want to learn more?
In addition to reporting clinical trial news and stories from within the patient community, we operate Citrus, a fully integrated recruitment and retention software. Citrus fits any clinical trial and simplifies the implementation of patient engagement in your clinical trial. Whether you are already working with CTMS systems or not, Citrus is the perfect add-on to make patient interaction effective.
Since 2015, our team has been hard at work raising awareness of clinical trials across the globe. A Forbes ‘30 Under 30’ company and a graduate of the renowned Techstar program in New York, Citruslabs is at the forefront of patient recruitment and retention technologies. With over 3 million patients now recorded on our databases, our patient recruitment dashboard is fast becoming the most efficient method of trial recruitment.
Now a #1 health app in 17 countries, our Mindmate app is helping to revolutionize the way we think about healthcare. Mindmate “[takes] senior care into the digital age” (Forbes, 2018) by providing people with the cognitive decline the essential tools to help them rebuild and maintain strong mental health. Trusted by millions of users, our health community continues to grow as the content available expands to the needs of individuals today.
With more than 200 research sites now using the Citrus platform to screen thousands of patients every month, researchers are now well on their way to finding new treatments for hundreds of different health conditions - something that just would not be possible without a technological solution. Make sure that your clinical trial is in the lucky 12% and turn that luck into guaranteed results with Citrus.
Check out what our customers have to say about us here.
And If you’d like to know more about how Citruslabs can help you recruit more effectively, get in touch with our team here.